Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.

Goodman, Rachel S; Jung, Seungyeon; Balko, Justin M; Johnson, Douglas B

Goodman, Rachel S; Jung, Seungyeon; Balko, Justin M; Johnson, Douglas B.

Afiliação

Goodman RS; Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Jung S; Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Balko JM; Department of Medicine, Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Johnson DB; Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Immunol Rev ; 318(1): 157-166, 2023 09.

Article em En | MEDLINE | ID: mdl-37470280

Assuntos

Neoplasias Encefálicas; Neoplasias Colorretais; Síndromes Neoplásicas Hereditárias; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Biomarcadores; Imunoterapia/efeitos adversos; Biomarcadores Tumorais

Palavras-chave

MHC-II; biomarkers; immune checkpoint inhibitors; immune-related adverse events; immunotherapy; tumor mutational burden

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias Encefálicas / Neoplasias Colorretais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google